Form 8-K

8-K — Tonix Pharmaceuticals Holding Corp.

Accession: 0001493152-26-036740

Filed: 2026-08-10

Period: 2026-08-10

CIK: 0001430306

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.01 (ex99-01.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001430306

2026-08-10

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of report (date of earliest event reported): August 10, 2026

TONIX

PHARMACEUTICALS HOLDING CORP.

(Exact

name of registrant as specified in its charter)

Nevada

001-36019

26-1434750

(State

or Other Jurisdiction

Incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

200

Connell Drive, Suite 3100, Berkeley Heights, New Jersey 07922

(Address

of principal executive offices) (Zip Code)

Registrant’s

telephone number, including area code: (862) 799-8599

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock

TNXP

The

NASDAQ Global Select Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02 Results

of Operations and Financial Condition.

August 10, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended

June 30, 2026. A copy of the press release that discusses this matter is filed as Exhibit 99.01 to, and incorporated by reference in,

this report.

Item

9.01

Financial

Statements and Exhibits.

(d)

Exhibit

No.

Description.

99.01

Press Release of the Company, dated August 10, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant

to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the

undersigned thereunto duly authorized.

TONIX

PHARMACEUTICALS HOLDING CORP.

Date:

August 10, 2026

By:

/s/

Bradley Saenger

Bradley

Saenger

Chief

Financial Officer

EX-99.01

Filename: ex99-01.htm · Sequence: 2

Exhibit

99.01

Tonix

Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

TONMYA®

net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter

Commercial

and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S.

lives)

First

patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive

disorder (MDD)

Phase

2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S. on track to start in the first quarter of 2027 pending

final FDA review and agreement on study protocol

Approximately

$176.2 million in cash and cash equivalents as of June 30, 2026

Conference

call today at 8:30 a.m. ET

BERKELEY

HEIGHTS, N.J., August 10, 2026 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or

the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced financial results for the

quarter ended June 30, 2026, and provided an overview of recent operational highlights.

“We

are pleased with the execution of TONMYA’s launch, including nearly tripling net sales and achieving growth across our key metrics

in the second quarter,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals. “We are

seeing TONMYA’s value resonate among healthcare providers and patients as the first FDA-approved treatment for fibromyalgia in

15 years. It is a first-in-class, non-opioid analgesic designed for daily bedtime administration and long-term use. We are now beginning

to see coverage translate into broader patient access following the execution of agreements with commercial payers, managed Medicare,

and Medicaid. Our newly expanded sales force is expected to deploy in the field by September. We believe we are well positioned to reach

more of our target prescribers and support the treatment of more patients with TONMYA.”

Dr.

Lederman continued, “We are also progressing our clinical development pipeline priorities. We enrolled the first patient in HORIZON,

our potentially pivotal Phase 2 study of TNX-102 SL in MDD. For Lyme prevention, we expect to start enrollment in the first quarter of

2027 in a Phase 2 adaptive field study after we reached alignment with FDA on the development path for TNX-4800, an investigational long-acting

borreliacidal human monoclonal antibody targeting OspA on Borrelia burgdorferi.”

Commercial

Updates

TONMYA

(cyclobenzaprine HCl sublingual tablets): a centrally acting, non-opioid analgesic for the treatment of fibromyalgia in adults; commercially

launched on November 17, 2025

Performance

Across Key Metrics

● In

the second quarter of 2026, key metrics include:

○ 12,592

total prescriptions, increasing 100% quarter-over-quarter. This includes bridge prescriptions

that are facilitated through the Company’s digital pharmacy channel. Bridge prescriptions

represent initial patient fills provided while coverage determinations are pending and do

not immediately generate net product revenue.

○ New

patient prescriptions increased 36% quarter-over-quarter.

○ Refills

increased 207% quarter-over-quarter.

Payer

Access and Coverage

● The

Company is prioritizing ongoing engagement with commercial payers, managed Medicare, and

Medicaid to increase access:

○ Tonix

announced commercial payer agreements with two leading GPOs in May and June 2026, providing

access to a combined approximate 52 million lives (29% of the total commercial lives in the

U.S.).

○ Currently,

total coverage for TONMYA across commercial, managed Medicare, and Medicaid channels represents

approximately 136 million covered lives (~43% of the approximately 314 million covered lives

in the U.S.).

○ When

the managed Medicare payer coverage agreement goes into effect on January 1, 2027, it will

add approximately nine million Medicare lives (16% of the approximately 55 million Medicare

lives in the U.S.). Total coverage will then reach approximately 145 million covered lives

(~46% of the 314 million covered lives in the U.S.).

○ TONMYA

is covered under Medicaid in most states, representing approximately 75 million lives.

Commercial

Execution

● Following

these coverage milestones and encouraging trends across launch key performance indicators,

Tonix is implementing its strategy to expand the TONMYA sales force. The Company expects

to deploy 50 new sales representatives in the field by September 2026, bringing the full

sales force to approximately 150 people.

● In

parallel, the Company is advancing marketing activities to enhance understanding of fibromyalgia

and product awareness among patients and healthcare providers, as well as non-commercial

medical affairs initiatives.

● In

the second quarter of 2026, Tonix presented data highlighting TONMYA at the European Alliance

of Associations for Rheumatology (EULAR) 2026, 2026 American Society of Clinical Psychopharmacology

(ASCP) Annual Meeting, and Professional Society for Health and Outcomes Research (ISPOR 2026)

Annual Meeting, as well as published a manuscript in the peer-reviewed journal, Clinical

Pharmacology in Drug Development.

Key

Product Pipeline Candidates: Recent Highlights

Central

Nervous System (CNS) Pipeline

TNX-102

SL (cyclobenzaprine HCl sublingual tablets): in Phase 2 development for MDD

● In

June 2026, Tonix enrolled the first patient in HORIZON, a potentially pivotal, 6-week, randomized,

double-blind, placebo-controlled Phase 2 study of TNX-102 SL 5.6 mg as a first-line monotherapy

in adults with MDD. Approximately 360 patients are expected to enroll at approximately 30

U.S. sites, with the primary endpoint of change from baseline in MADRS (Montgomery-Asberg

Depression Rating Scale) total score at Week 6. TNX-102 SL targets disturbed sleep through

antagonism at four neuronal receptors, an approach mechanistically distinct from currently

available antidepressants.

TNX-102

SL: in Phase 2 development for acute stress disorder (ASD) and acute stress reaction (ASR)

● The

U.S. Department of Defense-funded Optimizing Acute Stress Reaction Interventions (OASIS)

study is being conducted by the University of North Carolina under an investigator-initiated

IND. Topline data is expected to be reported mid-2027.

TNX-1300

(double-mutant cocaine esterase) for cocaine intoxication; Phase 2 program has Breakthrough Therapy designation from the FDA, with no

products on the market for this indication

● The

Company plans to meet with the FDA in 2026 to inform the clinical design of the next Phase

2 study (a Phase 2 study has been completed).

Infectious

Disease Pipeline

TNX-4800

(anti-OspA mAb): Phase 2-ready long-acting human monoclonal antibody in development for the seasonal prevention of Lyme disease in the

U.S., for which no FDA-approved vaccines or prophylactics are available

● The

Company received final minutes from a Type C meeting held with the FDA in early third quarter

of 2026. The adaptive Phase 2 field study is expected to start in the first quarter of 2027

pending final FDA review and agreement on the study protocol.

● The

study will be a randomized, double-blind, placebo-controlled field study, with the primary

efficacy endpoint of protection through six months, and a key secondary efficacy endpoint

of protection through three months. Adults aged 18 and older from U.S. Lyme-endemic areas

who engage in activities that increase their risk of deer tick bites will be randomized to

receive placebo or two doses of TNX-4800: 450 mg subcutaneous (SC) dose at Day 1, and a second

dose of 450 mg SC dose three months later at Day 85.

● In

April 2026, Tonix presented Phase 1 data and announced plans for an adaptive Phase 2 field

study of TNX-4800 at the 4th Annual Ticks and Tickborne Diseases Symposium at

Johns Hopkins University.

● The

Company expects to deliver investigational product to the Phase 2 clinical study sites in

the first quarter of 2027.

TNX-801

(recombinant horsepox virus): an attenuated, minimally replicative, live virus vaccine candidate in pre-clinical development for the

prevention of smallpox and mpox

● In

July 2026, Tonix announced a new paper in the Journal of Virology describing new murine

models for investigating mpox pathogenesis. TNX-801 is expected to enter a Phase 1 study

in mid-2027 pending FDA clearance of the Investigational New Drug (IND) application.

TNX-4200

(broad-spectrum antiviral targeting CD45) for the prevention or treatment of high-lethality infections to improve the medical readiness

of military personnel in biological threat environments

● The

ongoing TNX-4200 program is supported by an up to $34 million contract over five years from

the Department of Defense’s Defense Threat Reduction Agency (DTRA). In the second quarter,

the project began its next project phase.

Immunology

Pipeline

TNX-1500

(dimeric Fc-modified anti-CD40L, humanized mAb): Phase 2-ready third-generation anti-CD40L for prophylaxis of kidney transplant rejection

and treatment of autoimmune diseases

● In

July 2026, the World Health Organization (WHO) included mosdaprubart as the proposed International

Nonproprietary Name (pINN) for TNX-1500, pending publication as a recommended INN.

● In

May 2026, Tonix announced the publication of Phase 1 clinical data for TNX-1500 in the Journal

of Clinical Immunology that support TNX-1500 as a potentially first-in-class, best-in-class,

third-generation anti-CD40L monoclonal antibody for the prevention of kidney transplant rejection.

● A

Phase 2, open-label, investigator-initiated study in adult kidney transplant patients at

Massachusetts General Hospital (MGH) is expected to initiate in the second half of 2026 pending

FDA clearance of MGH’s IND application. The study is expected to enroll five adult

kidney transplant recipients.

Rare

Disease Pipeline

TNX-2900

(intranasal potentiated oxytocin): in development for Prader-Willi syndrome, with Orphan Drug and Rare Pediatric Disease designation

that could potentially make Tonix eligible for a Priority Review Voucher upon approval

● Tonix

plans to initiate a Phase 2, randomized, double-blind, placebo-controlled study in children

and adolescents with Prader-Willi syndrome in the second half of 2027.

Immuno-oncology

Pipeline

TNX-1700

(TFF2-albumin fusion protein): in preclinical development for gastric and colorectal cancer

● In

June 2026, Tonix presented preclinical data at the Ninth JCA-AACR Special Joint Conference

on Novel Therapies and Diagnostics in Upper Digestive and Head and Neck Cancers demonstrating

TNX-1700 normalizes myelopoiesis and enhances anti-PD-1 therapy in gastric cancer.

Financial:

Recent Highlights

Tonix

had approximately $176.2 million of cash and cash equivalents as of June 30, 2026, compared to approximately $207.6 million as of December

31, 2025. Net cash used in operating activities was approximately $84.6 million for the six months ended June 30, 2026, compared to $31.4

million for the same period in 2025.

Subsequent

to quarter-end, the Company raised $3.7 million in proceeds under its At-the-Market facility.

The

Company believes that its cash resources as of June 30, 2026, together with the net proceeds that it raised from equity offerings in

the third quarter of 2026 to date, will meet its planned operating and capital expenditure requirements into early second quarter of

2027.

of August 7, 2026, the Company had 17,151,024 shares of common stock outstanding.

Second

Quarter 2026 Financial Results

Net

product revenue for the second quarter 2026 was approximately $13.5 million, compared to $2.0 million for the same period in 2025, and

consisted of combined net sales of TONMYA, Zembrace® SymTouch®, and Tosymra®. Net revenue from sales of TONMYA for the second

quarter was approximately $11.0 million. Net revenue from sales of Zembrace SymTouch and Tosymra was approximately $2.5 million, compared

to $2.0 million for the same quarter in 2025. Cost of sales for the second quarter 2026 was approximately $0.7 million, compared to $3.3

million for the same period in 2025. The decrease in the cost of sales is predominantly driven by a change in product mix and a write-off

related to the migraine products in 2025.

Research

and development expenses for the second quarter 2026 were approximately $19.4 million, compared to $10.8 million for the same period

in 2025. The increase of $8.6 million was primarily attributable to higher manufacturing and clinical trial costs associated with advancing

the Company’s prioritized pipeline programs, as well as increased employee-related costs reflecting expanded headcount.

Selling,

general, and administrative expenses for the second quarter 2026 were approximately $36.0 million, compared to $16.2 million for the

same period in 2025. The increase of $19.8 million was primarily attributable to sales and marketing investment supporting the commercial

launch of TONMYA and the Company’s migraine products, together with increased employee-related and professional expenses.

Net

loss available to common stockholders was $40.6 million, or $2.44 per basic and diluted share, for the second quarter 2026, compared

to net loss available to common stockholders of $28.3 million, or $3.86 per basic and diluted share, for the same period in 2025. The

basic and diluted weighted average common shares outstanding for the second quarter 2026 was 16,635,254 compared to 7,327,257 shares

for the same period in 2025.

Conference

Call and Webcast Information

The

Company will host a conference call and webcast to report second quarter 2026 financial results and operational highlights on Monday,

August 10, 2026, at 8:30 a.m. ET.

listen to the conference call, register at this link. To view the webcast, register at this link.

replay will be available under “IR Events” in the Investors section of the Company’s website at https://ir.tonixpharma.com/news-events/ir-events.

Tonix

Pharmaceuticals Holding Corp.

Tonix

Pharmaceuticals* is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders,

infectious diseases, immunology conditions, and rare diseases with high unmet medical needs. TONMYA® (cyclobenzaprine HCl sublingual

tablets 2.8mg), the Company’s flagship internally conceived and developed medicine, is the first treatment for fibromyalgia in

more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products,

Zembrace® SymTouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is extending the science

behind TONMYA in Phase 2 clinical studies to evaluate the potential of TNX-102 SL in major depressive disorder and acute stress disorder/acute

stress reaction. Tonix is also advancing a pipeline of infectious disease programs, including monoclonal antibody TNX-4800 (anti-OspA

mAb) for Lyme disease prevention in the U.S. and TNX-801 (horsepox, live virus vaccine), a vaccine in development for the prevention

of mpox and smallpox. Within immunology, Tonix is developing TNX-1500 (anti-CD40L mAb), a third-generation CD40 ligand inhibitor for

the prevention of kidney transplant rejection. Finally, the Company’s rare disease portfolio includes TNX-2900, which is Phase

2 ready for the treatment of Prader-Willi syndrome. To learn more, visit www.tonixpharma.com.

*Tonix’s

product development candidates, including TNX-102 SL for new, unapproved indications, are investigational new drugs or biologics. Their

efficacy and safety have not been established and have not been approved for any indication.

Zembrace

SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other

marks are property of their respective owners.

Forward

Looking Statements

Certain

statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including

those relating to the Company’s expected financial performance, the Company’s anticipated cash runway, the Company’s

expected timelines regarding its clinical and pre-clinical programs, expected enrollment in the Company’s clinical trials, expected

adoption by the medical community and patients of the Company’s products and expected timelines regarding the Company’s manufacturing

processes. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,”

“forecast,” “estimate,” “expect,” and “intend,” among others. There are a number of factors

that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but

are not limited to, risks related to the failure to successfully launch and commercialize TONMYA® and any of our approved products;

risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing

and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection

and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence

upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development,

regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking

statement. Investors should read the risk factors set in the Company’s Annual Report on Form 10-K for the year ended December 31,

2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake

an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified

by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor

Contacts

Deborah

Elson

Tonix

Pharmaceuticals

deborah.elson@tonixpharma.com

investor.relations@tonixpharma.com

Brian

Korb

astr

partners

(917)

653-5122

brian.korb@astrpartners.com

Media

Contacts

Andrea

Cohen

Sam

Brown Inc.

(917)

209-7163

andreacohen@sambrown.com

TONIX

PHARMACEUTICALS HOLDING CORP.

CONDENSED

CONSOLIDATED STATEMENTS OF OPERATIONS

(In

Thousands, Except Share and Per Share Amounts)

(unaudited)

Three

Months Ended

June 30,

Six

Months Ended

June 30,

2026

2025

2026

2025

REVENUE:

Product revenue, net

$ 13,544

$ 1,998

$ 20,422

$ 4,427

COSTS AND EXPENSES:

Cost of revenue

703

3,272

2,281

4,215

Research and development

19,417

10,820

37,630

18,256

Selling, general and administrative

35,959

16,202

64,583

26,306

56,079

30,294

104,494

48,777

Operating loss

(42,535 )

(28,296 )

(84,072 )

(44,350 )

Grant income

600

1,036

600

1,959

Loss on extinguishment of debt

—

(2,092 )

Interest income, net

1,432

943

2,778

1,571

Other expense, net

(49 )

(1,955 )

(52 )

(2,189 )

Net loss available to

common stockholders

$ (40,552 )

$ (28,272 )

$ (80,746 )

$ (45,101 )

Net loss per common

share, basic and diluted

$ (2.44 )

$ (3.86 )

$ (5.32 )

$ (6.80 )

Weighted average common

shares outstanding, basic and diluted

16,635,254

7,327,257

15,179,268

6,631,111

TONIX

PHARMACEUTICALS HOLDING CORP.

CONDENSED

CONSOLIDATED BALANCE SHEETS

(In

Thousands)

(Unaudited)

June

30, 2026

December

31, 2025

Assets

Cash and cash equivalents

$ 176,232

$ 207,637

Accounts Receivable, net

11,805

6,271

Inventory

4,678

6,013

Prepaid expenses and other

10,717

8,955

Total current assets

203,432

228,876

Other non-current assets

50,656

48,295

Total assets

$ 254,088

$ 277,171

Liabilities and stockholders’

equity

Total liabilities

$ 31,807

$ 32,021

Stockholders’ equity

222,281

245,150

Total liabilities and

stockholders’ equity

$ 254,088

$ 277,171

The

condensed consolidated balance sheet for the year ended December 31, 2025, has been derived from the audited financial statements

but do not include all of the information and footnotes required by accounting principles generally accepted in the United States

for complete financial statements.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Aug. 10, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 10, 2026

Entity File Number

001-36019

Entity Registrant Name

TONIX

PHARMACEUTICALS HOLDING CORP.

Entity Central Index Key

0001430306

Entity Tax Identification Number

26-1434750

Entity Incorporation, State or Country Code

Entity Address, Address Line One

200

Connell Drive

Entity Address, Address Line Two

Suite 3100

Entity Address, City or Town

Berkeley Heights

Entity Address, State or Province

Entity Address, Postal Zip Code

07922

City Area Code

(862)

Local Phone Number

799-8599

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock

Trading Symbol

TNXP

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration